Published Data in Intrahepatic Cholangiocarcinoma

In the treatment of progressive or chemorefractory unresectable intrahepatic cholangiocarcinoma (ICC), a prospective study evaluated SIR-Spheres^® Y-90 resin microspheres as a well-tolerated and efficacious treatment option. The study included patients with bilobar disease, substantial tumour burden and liver involvement, extra-hepatic metastases, infiltrative disease, and/or an Eastern Cooperative Oncology Group (ECOG) performance status of 0–2.¹

Disease control rates of up to 79% have been reported with SIR-Spheres Y-90 resin microspheres for ICC.² Survival rates after 1, 2 and 3 years of 40%, 27%, and 13%, respectively, were reported in patients with unresectable nodular ICC who failed chemotherapy and/or recurred following surgical resection treated with SIR-Spheres Y-90 resin microspheres.¹ Survival may be more favourable when patients have an ECOG performance status of 0 vs. ≥1, a peripheral morphological tumour type,¹ or prior treatment with transarterial chemoembolisation (TACE).² However, survival was not significantly affected by presence or absence of extrahepatic metastasis; tumour burden ≤25% vs. 26-50%; or bilobar vs. unilobar tumour distribution.¹

SIRT with SIR-Spheres Y-90 resin microspheres is an efficacious treatment for unresectable ICC, with an acceptable adverse event profile.

1 Saxena A et al. Ann Surg Oncol 2010; 17: 484-491.
2 Rafi S et al. Cardiovasc Intervent Radiol 2013; 36: 440-448.